Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent refers to an inactivated split influenza vaccine whose vaccine components include A (H3N2) subtype, A (H1N1) pdm09 subtype, and type B Victoria and Yamagata lines.
According to our (Global Info Research) latest study, the global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.
This report is a detailed and comprehensive analysis for global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Hualan Bacterin, Sinovac Biotech, Sanofi, CSL Seqirus, GSK, Adimmune, Sinopharm, Jiangsu GDK Biotechnology, Abbott, Ab&B BIO-TECH, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, with price, sales quantity, revenue, and global market share of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent from 2019 to 2024.
Chapter 3, the Influenza Vaccine (Split Virion), Inactivated, Quadrivalent competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Influenza Vaccine (Split Virion), Inactivated, Quadrivalent breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent.
Chapter 14 and 15, to describe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent sales channel, distributors, customers, research findings and conclusion.
According to our (Global Info Research) latest study, the global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.
This report is a detailed and comprehensive analysis for global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Hualan Bacterin, Sinovac Biotech, Sanofi, CSL Seqirus, GSK, Adimmune, Sinopharm, Jiangsu GDK Biotechnology, Abbott, Ab&B BIO-TECH, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Child
- Adult
- Elder
- Hospital
- Clinic
- Hualan Bacterin
- Sinovac Biotech
- Sanofi
- CSL Seqirus
- GSK
- Adimmune
- Sinopharm
- Jiangsu GDK Biotechnology
- Abbott
- Ab&B BIO-TECH
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, with price, sales quantity, revenue, and global market share of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent from 2019 to 2024.
Chapter 3, the Influenza Vaccine (Split Virion), Inactivated, Quadrivalent competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Influenza Vaccine (Split Virion), Inactivated, Quadrivalent breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Influenza Vaccine (Split Virion), Inactivated, Quadrivalent market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent.
Chapter 14 and 15, to describe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Child
1.3.3 Adult
1.3.4 Elder
1.4 Market Analysis by Application
1.4.1 Overview: Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Clinic
1.5 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size & Forecast
1.5.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (2019-2030)
1.5.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Hualan Bacterin
2.1.1 Hualan Bacterin Details
2.1.2 Hualan Bacterin Major Business
2.1.3 Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
2.1.4 Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Hualan Bacterin Recent Developments/Updates
2.2 Sinovac Biotech
2.2.1 Sinovac Biotech Details
2.2.2 Sinovac Biotech Major Business
2.2.3 Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
2.2.4 Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Sinovac Biotech Recent Developments/Updates
2.3 Sanofi
2.3.1 Sanofi Details
2.3.2 Sanofi Major Business
2.3.3 Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
2.3.4 Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Sanofi Recent Developments/Updates
2.4 CSL Seqirus
2.4.1 CSL Seqirus Details
2.4.2 CSL Seqirus Major Business
2.4.3 CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
2.4.4 CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 CSL Seqirus Recent Developments/Updates
2.5 GSK
2.5.1 GSK Details
2.5.2 GSK Major Business
2.5.3 GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
2.5.4 GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 GSK Recent Developments/Updates
2.6 Adimmune
2.6.1 Adimmune Details
2.6.2 Adimmune Major Business
2.6.3 Adimmune Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
2.6.4 Adimmune Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Adimmune Recent Developments/Updates
2.7 Sinopharm
2.7.1 Sinopharm Details
2.7.2 Sinopharm Major Business
2.7.3 Sinopharm Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
2.7.4 Sinopharm Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Sinopharm Recent Developments/Updates
2.8 Jiangsu GDK Biotechnology
2.8.1 Jiangsu GDK Biotechnology Details
2.8.2 Jiangsu GDK Biotechnology Major Business
2.8.3 Jiangsu GDK Biotechnology Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
2.8.4 Jiangsu GDK Biotechnology Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Jiangsu GDK Biotechnology Recent Developments/Updates
2.9 Abbott
2.9.1 Abbott Details
2.9.2 Abbott Major Business
2.9.3 Abbott Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
2.9.4 Abbott Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Abbott Recent Developments/Updates
2.10 Ab&B BIO-TECH
2.10.1 Ab&B BIO-TECH Details
2.10.2 Ab&B BIO-TECH Major Business
2.10.3 Ab&B BIO-TECH Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
2.10.4 Ab&B BIO-TECH Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Ab&B BIO-TECH Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: INFLUENZA VACCINE (SPLIT VIRION), INACTIVATED, QUADRIVALENT BY MANUFACTURER
3.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Manufacturer (2019-2024)
3.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Manufacturer (2019-2024)
3.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Manufacturer Market Share in 2023
3.4.3 Top 6 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Manufacturer Market Share in 2023
3.5 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market: Overall Company Footprint Analysis
3.5.1 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market: Region Footprint
3.5.2 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market: Company Product Type Footprint
3.5.3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Region
4.1.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Region (2019-2030)
4.1.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Region (2019-2030)
4.1.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Region (2019-2030)
4.2 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030)
4.3 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030)
4.4 Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030)
4.5 South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030)
4.6 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2030)
5.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Type (2019-2030)
5.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2030)
6.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Application (2019-2030)
6.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2030)
7.2 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2030)
7.3 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Country
7.3.1 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2019-2030)
7.3.2 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2030)
8.2 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2030)
8.3 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Country
8.3.1 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2019-2030)
8.3.2 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Region
9.3.1 Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 South Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2030)
10.2 South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2030)
10.3 South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Country
10.3.1 South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2019-2030)
10.3.2 South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Country
11.3.1 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Drivers
12.2 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Restraints
12.3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent and Key Manufacturers
13.2 Manufacturing Costs Percentage of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
13.3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Typical Distributors
14.3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 Child
1.3.3 Adult
1.3.4 Elder
1.4 Market Analysis by Application
1.4.1 Overview: Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Clinic
1.5 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size & Forecast
1.5.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (2019-2030)
1.5.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Hualan Bacterin
2.1.1 Hualan Bacterin Details
2.1.2 Hualan Bacterin Major Business
2.1.3 Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
2.1.4 Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Hualan Bacterin Recent Developments/Updates
2.2 Sinovac Biotech
2.2.1 Sinovac Biotech Details
2.2.2 Sinovac Biotech Major Business
2.2.3 Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
2.2.4 Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Sinovac Biotech Recent Developments/Updates
2.3 Sanofi
2.3.1 Sanofi Details
2.3.2 Sanofi Major Business
2.3.3 Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
2.3.4 Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Sanofi Recent Developments/Updates
2.4 CSL Seqirus
2.4.1 CSL Seqirus Details
2.4.2 CSL Seqirus Major Business
2.4.3 CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
2.4.4 CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 CSL Seqirus Recent Developments/Updates
2.5 GSK
2.5.1 GSK Details
2.5.2 GSK Major Business
2.5.3 GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
2.5.4 GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 GSK Recent Developments/Updates
2.6 Adimmune
2.6.1 Adimmune Details
2.6.2 Adimmune Major Business
2.6.3 Adimmune Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
2.6.4 Adimmune Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Adimmune Recent Developments/Updates
2.7 Sinopharm
2.7.1 Sinopharm Details
2.7.2 Sinopharm Major Business
2.7.3 Sinopharm Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
2.7.4 Sinopharm Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Sinopharm Recent Developments/Updates
2.8 Jiangsu GDK Biotechnology
2.8.1 Jiangsu GDK Biotechnology Details
2.8.2 Jiangsu GDK Biotechnology Major Business
2.8.3 Jiangsu GDK Biotechnology Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
2.8.4 Jiangsu GDK Biotechnology Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Jiangsu GDK Biotechnology Recent Developments/Updates
2.9 Abbott
2.9.1 Abbott Details
2.9.2 Abbott Major Business
2.9.3 Abbott Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
2.9.4 Abbott Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Abbott Recent Developments/Updates
2.10 Ab&B BIO-TECH
2.10.1 Ab&B BIO-TECH Details
2.10.2 Ab&B BIO-TECH Major Business
2.10.3 Ab&B BIO-TECH Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
2.10.4 Ab&B BIO-TECH Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Ab&B BIO-TECH Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: INFLUENZA VACCINE (SPLIT VIRION), INACTIVATED, QUADRIVALENT BY MANUFACTURER
3.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Manufacturer (2019-2024)
3.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Manufacturer (2019-2024)
3.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Manufacturer Market Share in 2023
3.4.3 Top 6 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Manufacturer Market Share in 2023
3.5 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market: Overall Company Footprint Analysis
3.5.1 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market: Region Footprint
3.5.2 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market: Company Product Type Footprint
3.5.3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Region
4.1.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Region (2019-2030)
4.1.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Region (2019-2030)
4.1.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Region (2019-2030)
4.2 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030)
4.3 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030)
4.4 Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030)
4.5 South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030)
4.6 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2030)
5.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Type (2019-2030)
5.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2030)
6.2 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Application (2019-2030)
6.3 Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2030)
7.2 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2030)
7.3 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Country
7.3.1 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2019-2030)
7.3.2 North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2030)
8.2 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2030)
8.3 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Country
8.3.1 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2019-2030)
8.3.2 Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Region
9.3.1 Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 South Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2030)
10.2 South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2030)
10.3 South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Country
10.3.1 South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2019-2030)
10.3.2 South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Size by Country
11.3.1 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Drivers
12.2 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Restraints
12.3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent and Key Manufacturers
13.2 Manufacturing Costs Percentage of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
13.3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Typical Distributors
14.3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Hualan Bacterin Basic Information, Manufacturing Base and Competitors
Table 4. Hualan Bacterin Major Business
Table 5. Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
Table 6. Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Hualan Bacterin Recent Developments/Updates
Table 8. Sinovac Biotech Basic Information, Manufacturing Base and Competitors
Table 9. Sinovac Biotech Major Business
Table 10. Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
Table 11. Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Sinovac Biotech Recent Developments/Updates
Table 13. Sanofi Basic Information, Manufacturing Base and Competitors
Table 14. Sanofi Major Business
Table 15. Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
Table 16. Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Sanofi Recent Developments/Updates
Table 18. CSL Seqirus Basic Information, Manufacturing Base and Competitors
Table 19. CSL Seqirus Major Business
Table 20. CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
Table 21. CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. CSL Seqirus Recent Developments/Updates
Table 23. GSK Basic Information, Manufacturing Base and Competitors
Table 24. GSK Major Business
Table 25. GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
Table 26. GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. GSK Recent Developments/Updates
Table 28. Adimmune Basic Information, Manufacturing Base and Competitors
Table 29. Adimmune Major Business
Table 30. Adimmune Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
Table 31. Adimmune Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. Adimmune Recent Developments/Updates
Table 33. Sinopharm Basic Information, Manufacturing Base and Competitors
Table 34. Sinopharm Major Business
Table 35. Sinopharm Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
Table 36. Sinopharm Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Sinopharm Recent Developments/Updates
Table 38. Jiangsu GDK Biotechnology Basic Information, Manufacturing Base and Competitors
Table 39. Jiangsu GDK Biotechnology Major Business
Table 40. Jiangsu GDK Biotechnology Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
Table 41. Jiangsu GDK Biotechnology Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. Jiangsu GDK Biotechnology Recent Developments/Updates
Table 43. Abbott Basic Information, Manufacturing Base and Competitors
Table 44. Abbott Major Business
Table 45. Abbott Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
Table 46. Abbott Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 47. Abbott Recent Developments/Updates
Table 48. Ab&B BIO-TECH Basic Information, Manufacturing Base and Competitors
Table 49. Ab&B BIO-TECH Major Business
Table 50. Ab&B BIO-TECH Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
Table 51. Ab&B BIO-TECH Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 52. Ab&B BIO-TECH Recent Developments/Updates
Table 53. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 54. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Manufacturer (2019-2024) & (USD Million)
Table 55. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Manufacturer (2019-2024) & (US$/Unit)
Table 56. Market Position of Manufacturers in Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 57. Head Office and Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Production Site of Key Manufacturer
Table 58. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market: Company Product Type Footprint
Table 59. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market: Company Product Application Footprint
Table 60. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent New Market Entrants and Barriers to Market Entry
Table 61. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Mergers, Acquisition, Agreements, and Collaborations
Table 62. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Region (2019-2023-2030) & (USD Million) & CAGR
Table 63. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Region (2019-2024) & (K Units)
Table 64. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Region (2025-2030) & (K Units)
Table 65. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Region (2019-2024) & (USD Million)
Table 66. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Region (2025-2030) & (USD Million)
Table 67. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Region (2019-2024) & (US$/Unit)
Table 68. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Region (2025-2030) & (US$/Unit)
Table 69. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2024) & (K Units)
Table 70. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2025-2030) & (K Units)
Table 71. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Type (2019-2024) & (USD Million)
Table 72. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Type (2025-2030) & (USD Million)
Table 73. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Type (2019-2024) & (US$/Unit)
Table 74. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Type (2025-2030) & (US$/Unit)
Table 75. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2024) & (K Units)
Table 76. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2025-2030) & (K Units)
Table 77. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Application (2019-2024) & (USD Million)
Table 78. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Application (2025-2030) & (USD Million)
Table 79. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Application (2019-2024) & (US$/Unit)
Table 80. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Application (2025-2030) & (US$/Unit)
Table 81. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2024) & (K Units)
Table 82. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2025-2030) & (K Units)
Table 83. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2024) & (K Units)
Table 84. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2025-2030) & (K Units)
Table 85. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2019-2024) & (K Units)
Table 86. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2025-2030) & (K Units)
Table 87. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2019-2024) & (USD Million)
Table 88. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2025-2030) & (USD Million)
Table 89. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2024) & (K Units)
Table 90. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2025-2030) & (K Units)
Table 91. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2024) & (K Units)
Table 92. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2025-2030) & (K Units)
Table 93. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2019-2024) & (K Units)
Table 94. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2025-2030) & (K Units)
Table 95. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2019-2024) & (USD Million)
Table 96. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2025-2030) & (USD Million)
Table 97. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2024) & (K Units)
Table 98. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2025-2030) & (K Units)
Table 99. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2024) & (K Units)
Table 100. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2025-2030) & (K Units)
Table 101. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Region (2019-2024) & (K Units)
Table 102. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Region (2025-2030) & (K Units)
Table 103. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Region (2019-2024) & (USD Million)
Table 104. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Region (2025-2030) & (USD Million)
Table 105. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2024) & (K Units)
Table 106. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2025-2030) & (K Units)
Table 107. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2024) & (K Units)
Table 108. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2025-2030) & (K Units)
Table 109. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2019-2024) & (K Units)
Table 110. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2025-2030) & (K Units)
Table 111. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2019-2024) & (USD Million)
Table 112. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2025-2030) & (USD Million)
Table 113. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2024) & (K Units)
Table 114. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2025-2030) & (K Units)
Table 115. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2024) & (K Units)
Table 116. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2025-2030) & (K Units)
Table 117. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2019-2024) & (K Units)
Table 118. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2025-2030) & (K Units)
Table 119. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2019-2024) & (USD Million)
Table 120. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2025-2030) & (USD Million)
Table 121. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Raw Material
Table 122. Key Manufacturers of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Raw Materials
Table 123. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Typical Distributors
Table 124. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Typical Customers
Table 1. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Hualan Bacterin Basic Information, Manufacturing Base and Competitors
Table 4. Hualan Bacterin Major Business
Table 5. Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
Table 6. Hualan Bacterin Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Hualan Bacterin Recent Developments/Updates
Table 8. Sinovac Biotech Basic Information, Manufacturing Base and Competitors
Table 9. Sinovac Biotech Major Business
Table 10. Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
Table 11. Sinovac Biotech Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Sinovac Biotech Recent Developments/Updates
Table 13. Sanofi Basic Information, Manufacturing Base and Competitors
Table 14. Sanofi Major Business
Table 15. Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
Table 16. Sanofi Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Sanofi Recent Developments/Updates
Table 18. CSL Seqirus Basic Information, Manufacturing Base and Competitors
Table 19. CSL Seqirus Major Business
Table 20. CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
Table 21. CSL Seqirus Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. CSL Seqirus Recent Developments/Updates
Table 23. GSK Basic Information, Manufacturing Base and Competitors
Table 24. GSK Major Business
Table 25. GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
Table 26. GSK Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. GSK Recent Developments/Updates
Table 28. Adimmune Basic Information, Manufacturing Base and Competitors
Table 29. Adimmune Major Business
Table 30. Adimmune Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
Table 31. Adimmune Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. Adimmune Recent Developments/Updates
Table 33. Sinopharm Basic Information, Manufacturing Base and Competitors
Table 34. Sinopharm Major Business
Table 35. Sinopharm Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
Table 36. Sinopharm Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Sinopharm Recent Developments/Updates
Table 38. Jiangsu GDK Biotechnology Basic Information, Manufacturing Base and Competitors
Table 39. Jiangsu GDK Biotechnology Major Business
Table 40. Jiangsu GDK Biotechnology Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
Table 41. Jiangsu GDK Biotechnology Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. Jiangsu GDK Biotechnology Recent Developments/Updates
Table 43. Abbott Basic Information, Manufacturing Base and Competitors
Table 44. Abbott Major Business
Table 45. Abbott Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
Table 46. Abbott Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 47. Abbott Recent Developments/Updates
Table 48. Ab&B BIO-TECH Basic Information, Manufacturing Base and Competitors
Table 49. Ab&B BIO-TECH Major Business
Table 50. Ab&B BIO-TECH Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Product and Services
Table 51. Ab&B BIO-TECH Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 52. Ab&B BIO-TECH Recent Developments/Updates
Table 53. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 54. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Manufacturer (2019-2024) & (USD Million)
Table 55. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Manufacturer (2019-2024) & (US$/Unit)
Table 56. Market Position of Manufacturers in Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 57. Head Office and Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Production Site of Key Manufacturer
Table 58. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market: Company Product Type Footprint
Table 59. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market: Company Product Application Footprint
Table 60. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent New Market Entrants and Barriers to Market Entry
Table 61. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Mergers, Acquisition, Agreements, and Collaborations
Table 62. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Region (2019-2023-2030) & (USD Million) & CAGR
Table 63. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Region (2019-2024) & (K Units)
Table 64. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Region (2025-2030) & (K Units)
Table 65. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Region (2019-2024) & (USD Million)
Table 66. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Region (2025-2030) & (USD Million)
Table 67. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Region (2019-2024) & (US$/Unit)
Table 68. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Region (2025-2030) & (US$/Unit)
Table 69. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2024) & (K Units)
Table 70. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2025-2030) & (K Units)
Table 71. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Type (2019-2024) & (USD Million)
Table 72. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Type (2025-2030) & (USD Million)
Table 73. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Type (2019-2024) & (US$/Unit)
Table 74. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Type (2025-2030) & (US$/Unit)
Table 75. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2024) & (K Units)
Table 76. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2025-2030) & (K Units)
Table 77. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Application (2019-2024) & (USD Million)
Table 78. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Application (2025-2030) & (USD Million)
Table 79. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Application (2019-2024) & (US$/Unit)
Table 80. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Application (2025-2030) & (US$/Unit)
Table 81. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2024) & (K Units)
Table 82. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2025-2030) & (K Units)
Table 83. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2024) & (K Units)
Table 84. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2025-2030) & (K Units)
Table 85. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2019-2024) & (K Units)
Table 86. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2025-2030) & (K Units)
Table 87. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2019-2024) & (USD Million)
Table 88. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2025-2030) & (USD Million)
Table 89. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2024) & (K Units)
Table 90. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2025-2030) & (K Units)
Table 91. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2024) & (K Units)
Table 92. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2025-2030) & (K Units)
Table 93. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2019-2024) & (K Units)
Table 94. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2025-2030) & (K Units)
Table 95. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2019-2024) & (USD Million)
Table 96. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2025-2030) & (USD Million)
Table 97. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2024) & (K Units)
Table 98. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2025-2030) & (K Units)
Table 99. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2024) & (K Units)
Table 100. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2025-2030) & (K Units)
Table 101. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Region (2019-2024) & (K Units)
Table 102. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Region (2025-2030) & (K Units)
Table 103. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Region (2019-2024) & (USD Million)
Table 104. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Region (2025-2030) & (USD Million)
Table 105. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2024) & (K Units)
Table 106. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2025-2030) & (K Units)
Table 107. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2024) & (K Units)
Table 108. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2025-2030) & (K Units)
Table 109. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2019-2024) & (K Units)
Table 110. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2025-2030) & (K Units)
Table 111. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2019-2024) & (USD Million)
Table 112. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2025-2030) & (USD Million)
Table 113. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2019-2024) & (K Units)
Table 114. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Type (2025-2030) & (K Units)
Table 115. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2019-2024) & (K Units)
Table 116. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Application (2025-2030) & (K Units)
Table 117. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2019-2024) & (K Units)
Table 118. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity by Country (2025-2030) & (K Units)
Table 119. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2019-2024) & (USD Million)
Table 120. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Country (2025-2030) & (USD Million)
Table 121. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Raw Material
Table 122. Key Manufacturers of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Raw Materials
Table 123. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Typical Distributors
Table 124. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Typical Customers
LIST OF FIGURES
Figure 1. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Picture
Figure 2. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Type in 2023
Figure 4. Child Examples
Figure 5. Adult Examples
Figure 6. Elder Examples
Figure 7. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 8. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Application in 2023
Figure 9. Hospital Examples
Figure 10. Clinic Examples
Figure 11. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 12. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 13. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (2019-2030) & (K Units)
Figure 14. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Price (2019-2030) & (US$/Unit)
Figure 15. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Manufacturer in 2023
Figure 16. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Manufacturer in 2023
Figure 17. Producer Shipments of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent by Manufacturer Sales ($MM) and Market Share (%): 2023
Figure 18. Top 3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Manufacturer (Revenue) Market Share in 2023
Figure 19. Top 6 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Manufacturer (Revenue) Market Share in 2023
Figure 20. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Region (2019-2030)
Figure 21. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value Market Share by Region (2019-2030)
Figure 22. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 23. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 24. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 25. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 26. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 27. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Type (2019-2030)
Figure 28. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value Market Share by Type (2019-2030)
Figure 29. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Type (2019-2030) & (US$/Unit)
Figure 30. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Application (2019-2030)
Figure 31. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Application (2019-2030)
Figure 32. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Application (2019-2030) & (US$/Unit)
Figure 33. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Type (2019-2030)
Figure 34. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Application (2019-2030)
Figure 35. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Country (2019-2030)
Figure 36. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value Market Share by Country (2019-2030)
Figure 37. United States Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 38. Canada Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 39. Mexico Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 40. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Type (2019-2030)
Figure 41. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Application (2019-2030)
Figure 42. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Country (2019-2030)
Figure 43. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value Market Share by Country (2019-2030)
Figure 44. Germany Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 45. France Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 46. United Kingdom Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 47. Russia Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 48. Italy Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 49. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Type (2019-2030)
Figure 50. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Application (2019-2030)
Figure 51. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Region (2019-2030)
Figure 52. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value Market Share by Region (2019-2030)
Figure 53. China Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 54. Japan Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 55. South Korea Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 56. India Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 57. Southeast Asia Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 58. Australia Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 59. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Type (2019-2030)
Figure 60. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Application (2019-2030)
Figure 61. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Country (2019-2030)
Figure 62. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value Market Share by Country (2019-2030)
Figure 63. Brazil Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 64. Argentina Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 65. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Type (2019-2030)
Figure 66. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Application (2019-2030)
Figure 67. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Country (2019-2030)
Figure 68. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value Market Share by Country (2019-2030)
Figure 69. Turkey Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 70. Egypt Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 71. Saudi Arabia Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 72. South Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 73. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Drivers
Figure 74. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Restraints
Figure 75. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in 2023
Figure 78. Manufacturing Process Analysis of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
Figure 79. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Industrial Chain
Figure 80. Sales Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source
Figure 1. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Picture
Figure 2. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Type in 2023
Figure 4. Child Examples
Figure 5. Adult Examples
Figure 6. Elder Examples
Figure 7. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 8. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Application in 2023
Figure 9. Hospital Examples
Figure 10. Clinic Examples
Figure 11. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 12. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 13. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity (2019-2030) & (K Units)
Figure 14. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Price (2019-2030) & (US$/Unit)
Figure 15. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Manufacturer in 2023
Figure 16. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Manufacturer in 2023
Figure 17. Producer Shipments of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent by Manufacturer Sales ($MM) and Market Share (%): 2023
Figure 18. Top 3 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Manufacturer (Revenue) Market Share in 2023
Figure 19. Top 6 Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Manufacturer (Revenue) Market Share in 2023
Figure 20. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Region (2019-2030)
Figure 21. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value Market Share by Region (2019-2030)
Figure 22. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 23. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 24. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 25. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 26. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 27. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Type (2019-2030)
Figure 28. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value Market Share by Type (2019-2030)
Figure 29. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Type (2019-2030) & (US$/Unit)
Figure 30. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Application (2019-2030)
Figure 31. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Revenue Market Share by Application (2019-2030)
Figure 32. Global Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Average Price by Application (2019-2030) & (US$/Unit)
Figure 33. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Type (2019-2030)
Figure 34. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Application (2019-2030)
Figure 35. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Country (2019-2030)
Figure 36. North America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value Market Share by Country (2019-2030)
Figure 37. United States Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 38. Canada Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 39. Mexico Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 40. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Type (2019-2030)
Figure 41. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Application (2019-2030)
Figure 42. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Country (2019-2030)
Figure 43. Europe Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value Market Share by Country (2019-2030)
Figure 44. Germany Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 45. France Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 46. United Kingdom Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 47. Russia Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 48. Italy Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 49. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Type (2019-2030)
Figure 50. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Application (2019-2030)
Figure 51. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Region (2019-2030)
Figure 52. Asia-Pacific Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value Market Share by Region (2019-2030)
Figure 53. China Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 54. Japan Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 55. South Korea Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 56. India Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 57. Southeast Asia Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 58. Australia Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 59. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Type (2019-2030)
Figure 60. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Application (2019-2030)
Figure 61. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Country (2019-2030)
Figure 62. South America Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value Market Share by Country (2019-2030)
Figure 63. Brazil Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 64. Argentina Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 65. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Type (2019-2030)
Figure 66. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Application (2019-2030)
Figure 67. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Sales Quantity Market Share by Country (2019-2030)
Figure 68. Middle East & Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value Market Share by Country (2019-2030)
Figure 69. Turkey Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 70. Egypt Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 71. Saudi Arabia Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 72. South Africa Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Consumption Value (2019-2030) & (USD Million)
Figure 73. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Drivers
Figure 74. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Restraints
Figure 75. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in 2023
Figure 78. Manufacturing Process Analysis of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
Figure 79. Influenza Vaccine (Split Virion), Inactivated, Quadrivalent Industrial Chain
Figure 80. Sales Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source
